ARA-290
Also known as Cibinetide · EPO-derived Innate Repair Receptor agonist
New
Reconstitution & dosing guide
10 mg vial — research phases, recon steps, and a live unit calculator.
Available sizes & price
Catalog only10mg x 10 vials
ARA290 (Cibinetide) · Not in current stock
$30 / vial
Prices per vial · Research use only · Not medical advice.
Non-hematopoietic EPO-derived peptide studied for neuropathy and tissue-protective inflammation control.
How to picture it
Erythropoietin has tissue-protective messages separate from "make more red cells." ARA-290 is studied as a selective tissue-repair signal at that protective receptor (innate repair receptor) without the full hematologic push. Picture pressing the repair button on that receptor family without spinning up the blood factory — neuropathy and inflammatory-protection research find that separation useful.
Research focus & benefits
- Selective tissue-protective EPO-pathway research
- Neuropathy and inflammatory-protection studies
- Repair signaling without erythropoiesis push
Benefits describe research interest and pathway rationale — not guaranteed outcomes or medical advice. Research use only.
Overview
ARA-290 (cibinetide) is designed to activate the innate repair receptor without stimulating red blood cell production like erythropoietin. Clinical research has explored sarcoidosis-related small-fiber neuropathy and other inflammatory conditions.
Mechanism
Selective innate repair receptor (IRR) engagement → anti-inflammatory and tissue-protective signaling without erythropoiesis.
Research uses
- Small-fiber neuropathy
- Sarcoidosis symptom research
- Metabolic and neuropathic pain research
Research dosing notes
Investigational clinical dosing only where studied.
Half-life / kinetics
Short; frequent dosing in some study designs
Common research routes
Reported considerations
- Generally studied as well tolerated
- Injection-site reactions
- Trial-specific events
Contraindications / cautions
- Investigational constraints
- Pregnancy
Common research stacks
- Standard neuropathy care
- BPC-157 discussions (speculative)
Legal / access note
Investigational; not a general approved neuropathy cure-all.